Kidney Function in Sickle Cell Anemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03277547|
Recruitment Status : Recruiting
First Posted : September 11, 2017
Last Update Posted : January 9, 2018
This is a prospective clinical cohort study that involves a baseline study visit followed by up to 3 annual follow-up study visits for a total follow-up of 36-48 months to evaluate the age- and sex-adjusted rate of change in kidney function, and to identify biomarkers of endothelial function, metabolomic profiles and clinical characteristics for the worsening of kidney function and for a rapid decline in kidney function.
"Funding Source - FDA OOPD"
|Condition or disease|
|Sickle Cell Disease Kidney Failure, Chronic|
Sickle cell disease is a severe monogenic disorder which affects approximately 80,000 patients in the US. It is characterized by a vasculopathy with involvement of multiple organs and resulting in complications such as ischemic stroke, pulmonary hypertension, autosplenectomy, priapism, as well as chronic kidney disease (CKD). Despite the high prevalence of CKD and its known association with increased mortality, the natural history of CKD and the factors associated with changes in kidney function in patients with SCD remain incompletely defined. Furthermore, the available treatment options for albuminuria, an early manifestation of CKD, in patients with SCD are limited. In fact, no controlled studies have confirmed the long-term efficacy of angiotensin-converting enzyme (ACE) inhibitors, the current "standard of care." There is increasing evidence for a contribution of endothelial dysfunction to the pathophysiology of albuminuria in SCD. The association of biomarkers of endothelial function with albuminuria provides opportunities, not only to assess the effect of therapies which improve endothelial function, but also to evaluate the predictive value of these biomarkers for a decline in kidney function. The long-range goal is to develop a model to identify patients at particularly high risk for a decline in kidney function.
In this study, the investigators will evaluate rate of change in kidney function (decline in estimated glomerular filtration rates and increase in albuminuria) and identify biomarkers of endothelial function, metabolomic profiles and clinical characteristics for the worsening of kidney function and for a rapid decline in kidney function. At the conclusion of this proposed work, the investigators will have an improved understanding of the natural history of CKD in sickle cell anemia. With the limited available therapies for the treatment of albuminuria in SCD and the paucity of data on the long-term efficacy of available pharmacotherapies, identification of biomarkers for the progression of CKD will facilitate the development of treatments which may be more effective than the current "standard of care."
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||The Association of Biomarkers of Endothelial Function With Prospective Changes in Kidney Function in Sickle Cell Anemia|
|Actual Study Start Date :||November 17, 2017|
|Estimated Primary Completion Date :||August 2022|
|Estimated Study Completion Date :||August 2022|
- Age- and sex-adjusted rate of change, over 36 - 48 months, in estimated glomerular filtration rate in patients with sickle cell anemia [ Time Frame: 36-48 months ]Estimated glomerular filtration rate will be ascertained using the CKD EPI equation
- Age- and sex-adjusted rate of change, over 36 - 48 months, in albuminuria in patients with sickle cell anemia [ Time Frame: 36-48 months ]Evaluate the rate of change in albuminuria by spot urine measurements of albumin-creatinine ratio during designated study visits
- Cross-sectional association of biomarkers of endothelial function with kidney function (estimated glomerular filtration rate and albuminuria) in patients with sickle cell anemia [ Time Frame: 36-48 months ]Plasma levels of ET-1, VEGF and soluble VCAM-1 from samples obtained at designated study visits will serve as measures of endothelial function
- Cross-sectional association of urine and plasma metabolomics profiles with kidney function (estimated glomerular filtration rates and albuminuria) in patients with sickle cell anemia [ Time Frame: 36-48 months ]Untargeted metabolic profiling of plasma and urine will be performed using high-resonance nuclear magnetic resonance spectrometry. Plasma and urine analytes which are significantly associated with estimated glomerular filtration rate and albumin-creatinine ratio will be ascertained.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03277547
|United States, North Carolina|
|University of North Carolina-Chapel Hill||Recruiting|
|Chapel Hill, North Carolina, United States, 27599|
|Contact: Kenneth I Ataga, MD 919-843-7708 firstname.lastname@example.org|
|Contact: David Wichlan 919-966-6876 email@example.com|
|Principal Investigator: Kenneth I Ataga, MD|
|Sub-Investigator: Vimal K Derebail, MD, MPH|
|Sub-Investigator: Laila Elsherif, PhD|
|Sub-Investigator: Jianwen Cai, PhD|
|Sub-Investigator: Laura R Loehr, MD, PhD|
|Sub-Investigator: Jeffrey MacDonald, PhD|
|Sub-Investigator: Donglin Zeng, PhD|
|Sub-Investigator: Payal C Desai, MD|
|Principal Investigator:||Kenneth Ataga, MD||University of North Carolina, Chapel Hill|